Virbac announces transition of Globion into Virbac Biologicals to strengthen biologicals and vaccines platform

Mumbai-based Virbac Animal Health India has announced the successful integration of Globion into its ecosystem and its transition to Virbac Biologicals. This marks a significant milestone in strengthening Virbac’s biologicals and vaccines capabilities, with a focused emphasis on poultry.

The transition reflects the coming together of strong scientific expertise, advanced manufacturing capabilities, and a shared commitment to advancing animal health outcomes. It further reinforces Virbac’s long-term strategy of delivering high-quality, science-led, and trusted solutions to veterinarians, poultry farmers, and animal health stakeholders.

Virbac Biologicals will serve as a key pillar within Virbac’s animal health portfolio, enhancing its vaccines and biologicals platform and strengthening its ability to develop innovative solutions that support disease prevention, productivity, and sustainable animal healthcare.

Looking ahead, Virbac Biologicals will continue to focus on science, quality, innovation, and customer trust, while further strengthening its manufacturing and research capabilities to meet the evolving needs of the animal health sector.

“This integration brings together complementary scientific expertise and manufacturing strength, enabling us to better serve veterinarians, poultry farmers, and animal health stakeholders across IMEA. Our focus remains firmly on innovation, quality, and delivering trusted solutions that create long-term value for our customers and partners”, said Natesan Thanthoni, Area Director – India, Middle East & Africa (IMEA), Virbac Animal Health.